Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BIO · NYSE · United States · Laboratory Analytical Instruments
In shortBIO-RAD LABORATORIES, INC. is profitable, generates cash and holds more cash than debt, with revenue stable (+0.7% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 1.8% | 23/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 29.4% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 10.8% | 54/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 0.4% | 3/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 5.62× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.16× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.96× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 6.54 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 14.5% | 78/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.49× | 24/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 8.3% | 81/100 |
| Operating margin volatility | 6.3% | 52/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -2.7% | 2/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2,923 | 2,802 | 2,671 | 2,567 | 2,583 |
| Cost of revenue | 1,284 | 1,235 | 1,244 | 1,188 | 1,243 |
| Gross profit | 1,638 | 1,567 | 1,427 | 1,379 | 1,340 |
| Research & development | 261 | 257 | 247 | 296 | 276 |
| Selling, general & admin | 877 | 828 | 842 | 814 | 844 |
| Operating income | 500 | 483 | 338 | 269 | 47 |
| Interest expense | 1.6 | 38 | 49 | 49 | 49 |
| Pre-tax income | 5,449 | (4,704) | (850) | (2,343) | 996 |
| Income tax | 1,195 | (1,077) | (213) | (498) | 236 |
| Net income | 4,254 | (3,628) | (637) | (1,844) | 760 |
| Diluted EPS | $140.83 | −$121.79 | −$21.82 | −$65.36 | $27.85 |
| Diluted shares (millions) | 30 | 30 | 29 | 28 | 27 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
6.54 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 4, 2026